“These initial results are very exciting and confirm our belief that leronlimab has the potential to be materially beneficial for patients suffering from a number of medical concerns,” said Dr. Jacob Lalezari, CEO of CytoDyn.

Congrats to Dr J and to us all, one yard closer (maybe several) to paydirt!!!